Numer badania | Tytuł badania | Nowotwór | Kategoria chorych | Faza badania | Sponsor badania | Data rozpoczęcia | Data zakończenia | Ośrodki badawcze | Sponsor badania | Linki |
---|---|---|---|---|---|---|---|---|---|---|
NCT00790036 | Phase III Study of RAD001 Adjuvant Therapy in Poor Risk... | DLBCL | III/IV stopień, CR po chemioterapii z rytuksymabem | III | Novartis | 2009-06-30 | 2014-04-30 |
Bydgoszcz; Łódź; Lublin; Warszawa
|
Novartis | |
NCT01077518 | Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in... | chłoniak B-komórkowy | oporny na rituksymab | III | GSK | 2010-07-31 | 2022-04-30 |
Gdynia; Warszawa; Wrocław
|
GSK | |
NCT00472303 | A Study to Evaluate CG5503 in the Treatment of Chronic... | ból nowotworowy | zaawansowany nowotwór | III | Grunenthal | 2007-06-30 | 2012-03-31 |
Bydgoszcz; Warszawa
|
Grunenthal | |
NCT01337089 | Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as... | kontynuacja poprzedniego badania | III | GW Pharmaceuticals | 2010-12-31 | 2014-07-31 |
Bielsko-Biała; Gliwice; Poznań; Warszawa
|
GW Pharmaceuticals | ||
NCT00822614 | Safety of Fentanyl TAIFUN Treatment | choroba nowotworowa | ból przebijający | III | Akela Pharma | 2008-11-30 | 2009-12-31 |
Zbigniew Kaczmarek - Włocławek
|
Akela Pharma | |
NCT01100502 | A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients... | chłoniak Hodgkina | po przeszczepie | III | Seattle Genetics | 2010-03-31 | 2016-03-31 |
Klinika Hematologii UCK Gdańsk, Marcelina Paruch, Ph: +48 22 210... |
Seattle Genetics | |
NCT01232556 | A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive... | NHL | oporny/nawrotowy | III | Pfizer | 2011-03-31 | 2015-11-30 |
Warszawa
|
Pfizer | |
NCT00646854 | Alemtuzumab and CHOP in T-cell Lymphoma | chłoniak T-kom | 1sza linia leczenia | III | Aarhus Universitetshospital | 2008-05-31 | 2016-11-30 |
CO-I Warszawa; prof.J.Walewski, walewski@coi.waw.pl
|
Aarhus Universitetshospital | |
NCT00209222 | Efficacy of Rituximab - Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)... | chłoniak płaszcza | 1sza linia leczenia | III | University of Cologne | 2004-06-30 | 2010-05-31 |
Jan Walewski; Ph: +48-22-546-2223;
|
University of Cologne | |
NCT00209209 | Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus... | chłoniak płaszcza | 1. linia leczenia | III | University of Cologne | 2003-12-31 | 2013-12-31 |
CO-I Warszawa Jan Walewski; Ph: +48-22-546-2223; walewski@coi.waw.pl
|
University of Cologne |